QUOTE AND NEWS
Japan Today  May 15  Comment 
Japan's top drugmaker on Friday reported an annual loss for the first time in its history after agreeing to pay $2.4 billion to settle U.S. lawsuits over cancer claims regarding its Actos diabetes drug. Osaka-based Takeda Pharmaceutical said...
FiercePharma  May 15  Comment 
In his debut earnings report since assuming his role as CEO of Japanese drugmaker Takeda, Christophe Weber had to tell investors today that the company had a small loss in its last fiscal year.
FiercePharma  May 14  Comment 
Turns out the FDA isn't the only one that's been ticked off with Orexigen since it released some early positive cardio data for obesity drug, Contrave, last March. Marketing partner Takeda is on that list, too--and earlier this week, the Japanese...
FiercePharma  May 13  Comment 
The FDA was none too happy with Orexigen when it put out some early positive cardio data for obesity drug Contrave in March. One reason? Early data can be misleading--and now, it looks like that might have been the case for Contrave.
TheStreet.com  May 13  Comment 
NEW YORK (TheStreet) -- Orexigen Therapeutics shares are down 9.60% to $5.36 in early market trading on Wednesday after the biopharmaceutical company's weight loss drug development partner Takeda Pharmaceutical threatened to end their...
FierceBiotech  May 13  Comment 
Alisertib, a jewel of Takeda's $8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing the Japanese drugmaker to pull the plug and pivot to other indications.
MedPage Today  May 12  Comment 
(MedPage Today) -- Orexigen and Takeda halt the Light Study after early outcomes data were publicly released.
New York Times  Apr 29  Comment 
Nearly 9,000 bladder cancer claims are pending against Takeda, which was accused of concealing the cancer risk of the big-selling medication.
New York Times  Apr 28  Comment 
Nearly 9,000 bladder cancer claims are pending against Takeda, which was accused of concealing the cancer risk of the big-selling medication.
FierceBiotech  Apr 17  Comment 
Takeda has struck up a 10-year partnership with Japan's Kyoto University to develop potential stem cell treatments for an array of diseases, committing about $270 million to the effort.




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki